Vagulienė, N. (2020). THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%. Pulmonology and Allergology, 4(2), 164-167. https://doi.org/10.37499/PIA.119